Consciousness has a structure with foreground contents and a background environment, a relation that depends on the brain's interaction with the body and external world. The temporo-spatial theory proposes that the brain aligns its neuronal activity to environmental stimuli across three layers: a background layer with longer timescales creating shared brain similarities across subjects, an intermediate layer with medium timescales matching environmental inputs to intrinsic neuronal rhythms, and a foreground layer with shorter timescales entraining to stimulus timing. These layers correspond to phenomenal layers: a shared contextual background, a layer mediating content relationships, and fast-changing specific contents. This alignment may bridge physical, dynamic, neuronal, and phenomenal mechanisms of consciousness.
A randomized controlled trial will test whether virtual-reality-guided meditation is feasible and acceptable for reducing stress, anxiety, and depression in older adults. Thirty community-dwelling adults aged 60 years or older with moderate stress will be randomly assigned to either an eight-session VR meditation program or a waitlist control group. Sessions last 15 minutes and occur twice weekly for four weeks, offered at home or in a hospital. Outcomes include perceived stress, anxiety, depression, sleep quality, quality of life, and mindfulness skills, measured before and after the intervention. Qualitative interviews will capture participants' experiences. The trial is registered at ClinicalTrials.gov (NCT05315609).
Late-life depression affects up to 18% of older adults and is linked to elevated dementia risk. Mindfulness-based cognitive therapy (MBCT) may help treat depressive symptoms and cognitive deficits in this population, but a definitive randomized controlled trial has not yet been conducted. This protocol describes a multi-site blinded trial comparing MBCT to an active control, a Health Enhancement Program, in 213 patients with late-life depression. Changes in depression severity, processing speed, executive functioning, and brain biomarkers will be assessed at baseline, post-intervention (8 weeks), and 26 weeks after baseline. The study will evaluate MBCT's potential to improve depression, cognitive impairments, and neurobiological markers.